| Literature DB >> 8096744 |
H Strander, H C Bauer, O Brosjö, A Kreicbergs, J Lindholm, U Nilsonne, C Silfverswärd, A Szamosi.
Abstract
An update of the adjuvant trial on osteosarcoma in Sweden comparing patients receiving natural interferon (IFN) alpha with a high-dose chemotherapy group and a nonadjuvant group is presented. The overall survival for the IFN group is 49%, for the chemotherapy group 54%, and for the nonadjuvant group 35%. Trial evaluation was complicated by group differences with respect to various clinicopathologic features of prognostic significance. The role of IFN in the treatment of osteosarcoma can still not be established.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8096744 DOI： 10.1007/978-1-4615-3518-8_5
Source DB: PubMed Journal: Cancer Treat Res ISSN： 0927-3042